Overview
Cytomegalovirus (CMV) is a human herpesvirus type 5, belonging to the double-stranded DNA herpesvirus family, as described in the document. CMV infection is widespread and often remains asymptomatic in healthy individuals, but it can cause serious illness in pregnant women, neonates, transplant recipients, and immunocompromised patients. Once infected, CMV remains latent in the body for life and can reactivate under certain conditions.
The Cytomegalovirus IgG and IgM antibody tests are serological investigations used to determine immune status, recent infection, past exposure, or viral reactivation. IgM antibodies indicate recent or active infection, while IgG antibodies indicate past exposure and immune memory. The document emphasizes that laboratory testing supports diagnosis, but clinical findings remain the cornerstone of CMV diagnosis, with serology used mainly for confirmation and immune status assessment.
Symptoms
Symptoms of Cytomegalovirus infection vary widely depending on the immune status of the individual, as outlined in the document. Many immunocompetent individuals experience mild or no symptoms, while high-risk groups may develop severe disease.
Common symptoms include:
- Fever
- Headache
- Fatigue
- Muscle pain
- Jaundice
In more severe cases, especially in immunocompromised individuals or neonates, symptoms may include:
- Pneumonia
- Retinitis leading to visual impairment
- Hepatomegaly and splenomegaly
- Gastrointestinal tract infection
- Bronchitis
In pregnancy and neonatal infection, CMV may be associated with:
- Premature delivery
- Stillbirth
- Recurrent abortions
- Seizures
- Hearing loss
The document highlights that Cytomegalovirus should be suspected when patients present with atypical or unexplained symptoms, particularly when immune function is compromised.
Causes
According to the document, CMV infection occurs when the virus enters the body and establishes primary infection, followed by lifelong latency. The virus causes a cytopathic effect, characterized by enlarged cells containing viral inclusion bodies.
CMV spreads through:
- Close personal contact
- Body fluids such as blood and secretions
- Organ transplantation
- Congenital transmission
The document explains that IgM antibodies rise during primary infection or reactivation, while IgG antibodies appear several weeks after infection, increase during the active phase, and then stabilize for long-term immunity. Importantly, reinfection or reactivation can occur even in individuals who were previously infected.
Risk Factors
Risk factors for Cytomegalovirus infection and reactivation are strongly related to immune status and physiological vulnerability, as detailed in the document.
Major risk factors include:
- Pregnancy
- Neonatal period
- Organ transplantation
- Immunosuppressive therapy
- HIV infection
Additional risk factors include:
- History of repeated abortions or stillbirths
- Premature infants
- Hospitalized patients with prolonged illness
- Individuals with suppressed immune systems
The document notes that Cytomegalovirus serology is particularly useful for determining susceptibility in pregnancy, assessing transplant compatibility, and monitoring immunocompromised patients, although molecular tests may be preferred in certain settings.
Prevention
Currently, no CMV vaccine is available, as clearly stated in the document. Cytomegalovirus vaccines remain in the research and development stage, with future availability anticipated.
Preventive strategies focus on early detection, immune status assessment, and clinical vigilance:
- Screening pregnant women to determine Cytomegalovirus susceptibility
- Monitoring transplant recipients and immunocompromised individuals
- Early testing when Cytomegalovirus infection is clinically suspected
- Avoiding delay in testing, especially in high-risk patients
From a diagnostic standpoint, prevention of complications relies on:
- Correct timing of antibody testing
- Understanding IgM and IgG antibody patterns
- Repeating testing in equivocal cases
- Integrating results with clinical findings
